melphalan + eribulin

**Melphalan + eribulin** is an investigational combination of two chemotherapeutic agents: melphalan, a bifunctional alkylating agent of the nitrogen mustard class, and eribulin, a non-taxane microtubule dynamics inhibitor and synthetic analog of halichondrin B. - **Melphalan** works by alkylating DNA and RNA, leading to crosslinking, inhibition of DNA replication and transcription, and subsequent cell death in both dividing and non-dividing tumor cells[5][6]. - **Eribulin** inhibits microtubule polymerization by binding tubulin at a unique site, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, thereby inducing irreversible mitotic block (G2-M phase arrest) and apoptosis[1][2]. Both drugs have shown activity in various malignancies and, while combination studies are documented with other agents, there is no documented evidence of clinical development or trials for the exact combination "melphalan + eribulin" as of September 2025[1][2][5].

Brand names

IvraPhelinun

Other names

melphalaneribulin mesylatemelphalan + eribulin